

OICR-0547

Chemical Properties

CAS No. : 1801873-49-3


Formula: C₂₈H₂₉F₃N₄O₄

Molecular Weight: 542.55

Store at low temperature

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429. OICR-9429 is an inhibitor of the interaction between WDR5 and the mixed leukaemia (MLL) protein.
Targets(IC50)	Others,JAK
In vitro	OICR-0547 (0.1-100 μM) was used to treat K562 cells and Cebpap30/p30 cells. OICR-0547 had no effect on the viability of either cell line. [1]
In vivo	OICR-0547 (3 mg/kg, intravenous injection) and (30 mg/kg, intraperitoneal injection) can be used as a negative control model in NOD-SCID mice.[2]

Solubility Information

Solubility	DMSO: 180 mg/mL (331.77 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (7.37 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8431 mL	9.2157 mL	18.4315 mL
5 mM	0.3686 mL	1.8431 mL	3.6863 mL
10 mM	0.1843 mL	0.9216 mL	1.8431 mL
50 mM	0.0369 mL	0.1843 mL	0.3686 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Grebien F, et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBP α N-terminal leukemia. *Nat Chem Biol.* 2015 Aug;11(8):571-578.

Matthäus Getlik, et al. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1). *J Med Chem.* 2016 Mar 24;59(6):2478-96.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481